期刊文献+

低分子肝素聚乳酸-羟基乙酸缓释微球的研制

Research and development of LWMH-PLGA controlled-release microspheres
暂未订购
导出
摘要 目的制备低分子肝素聚乳酸-羟基乙酸(LWMH-PLGA)缓释微球,观察微球表面形态,检测微球物理性能和体外释药行为。方法采用W1/O/W2复乳溶剂挥发法制作微球;通过扫描电镜观察微球的表面形态结构;利用天青A比色法测试微球中药物的载药量和包封率,并对微球中药物的体外释放行为进行研究。结果微球表面显现较多的孔隙,平均粒径为(2.55±0.94)μm,载药量为(14.79±1.03)%,包封率为(55.7±2.21)%;48 h的体外释放试验表明,LWMH累积释放率达到40%。结论 LWMH-PLGA微球能够稳定地释放药物LWMH,验证了PLGA微球作为LWMH控制释放载体的可行性。 Purpose To prepare LWMH-PLGA microspheres and to investigate the characteristics. Methods The LWMH-PLGA microspheres were prepared by W1/O/W2 multiple emulsion volatilizing method,the morphology was investigated using scanning electron microscope (SEM) and the UV-Vis method was used to establish the regression equation and to detect the drug loading amount and encapsu- lation efficiency,as well as sustained-release profile in vitro. Results The microsphere surfaces seemed to be with sporadic pores and uniform with mean particle size of (2.55 ± 0.94) μm. The drug loading a- mount and encapsulation efficiency were ( 14.79 ±1.03 ) % and (55.7 ± 2.21 ) %, respectively. The ac- cumulative release ratio was up to 40% in the continuous PLGA microspheres have better pharmaceutical properties period of two days. Conclusion The LWMH- and sustained release effect in vitro
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2012年第5期600-602,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 低分子肝素 聚乳酸-羟基乙酸微球 缓释 LWMH PLGA microspheres sustained release
  • 相关文献

参考文献6

二级参考文献40

  • 1孔德新,张天民.肝素类化合物的经皮吸收制剂[J].中国生化药物杂志,1993,14(2):1-3. 被引量:1
  • 2崔慧斐,张天民.肝素口服制剂的研究[J].中国生化药物杂志,1993,14(4):3-6. 被引量:4
  • 3尹慧君,苏佳灿.碱性成纤维细胞生长因子促进骨折愈合的作用及机制[J].第二军医大学学报,2007,28(3):329-331. 被引量:4
  • 4Tabata Y. Tissue regeneration based on growth factor release[ J]. Tissue Eng,2003,9 (Suppl 1):S5-S15.
  • 5Detillieux K A, Cattini P A, Karadami E. Beyond angiogenesis:the cardioprotective potential of fibroblast growth factor-2 [J]. Can J Physiol Pharmacol, 2004,82 : 1044-1052.
  • 6Bosman F T, Stamenkovic I. Functional structure and composition of the extracellular matrix [ J]. J Pathol, 2003,200 : 423-428.
  • 7Layman H, Li S, Pham S M, et al. Therapeutic angiogenesis in critical limb ischemia via the localized delivery of bFGF from ionic hydrogels [J]. J Surg Res, 2006,130 : 265-270.
  • 8Kinsella L, Chen H L, Smith J A, et al. Interactions of putative heparin-binding domains of basic fibroblast growth facior and its receptor, FGFR- 1, with heparin using synthetic peptides [ J ]. Glycoconj J, 1998, 15:419-422.
  • 9Daniel B P, Shenshen C. Heparin-regulated release of growth factor in vivo and angiogenic response in vivo to implanted hydrogels containing VEGF and bFGF[ J ]. Biomaterials, 2006, ( 27 ) : 5242-5251.
  • 10Jaklenec A, Wan E, Murray M E, et al. Novel scaffolds fabricated from protein-loaded microspheres for tissue engineering [ J ]. Biomaterials, 2008,29: 185-192.

共引文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部